Advanced in Acute Myeloid Leukemia (AML)

Samia Harbi

Marseille, FR 
Advanced in Acute Myeloid Leukemia (AML)
Marseille, FR 
OverviewLocationsClinical Research

Overview

Samia Harbi practices in Marseille, France. Ms. Harbi is rated as an Advanced expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Graft Versus Host Disease (GvHD), Hodgkin Lymphoma, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 10 articles in the study of Acute Myeloid Leukemia (AML).

Gender
Female

Locations

Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Extension of a Phase III Randomized Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen-HaploMUD-RIC-01
Extension of a Phase III Randomized Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen-HaploMUD-RIC-01
Enrollment Status: Completed
Publish Date: October 04, 2024
Intervention Type: Procedure
Study Phase: Phase 3

49 Total Publications

Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
Journal: Bone marrow transplantation
Published: December 06, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Harbi's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile